Optic IconOptic Logo
|
SearchCollectionsBenchmarks
Clinical trial

Survival prEdiction in bLadder Cancer Patients Treated by nEoadjuvant Chemotherapy Before cysTectomy

ID
Name
2021/0393/HP
Description
This study will allow the investigators to better assess the efficiency of neoadjuvant chemotherapy before cystectomy by training a predictive model on different patient cohorts with bladder cancer.
Trial arms
Trial start
2023-04-01
Estimated PCD
2026-03-31
Trial end
2026-03-31
Status
Active (not recruiting)
Treatment
neoadjuvant chemotherapy with cisplatine
Blood from patient having muscle invasive bladder cancer who benefit from neoadjuvant chemotherapy with cisplatine
Arms:
Patients enrolled in VESPER study, Patients from COBLAnCE cohort not enrolled in VESPER study, Patients from St Louis cohort not enrolled in VESPER study
Size
707
Primary endpoint
Progression-free survival
3 years
Eligibility criteria
Inclusion Criteria: - Inclusion Criteria of Patients enrolled in VESPER study: Blood and tumors from patient having muscle invasive bladder cancer who benefit from neoadjuvant chemotherapy with cisplatine included in VESPER cohort and : having signed an informed consent form for the participation to the collection or dead/lost to follow-up without prior opposition expressed against research program, genetic analysis will only be carried out for patients who have signed the genetic consent form. - Inclusion Criteria of Patients from St Louis cohort not enrolled in VESPER study: Blood and tumors from patient having muscle invasive bladder cancer who benefit from neoadjuvant chemotherapy with cisplatine included in Saint-Louis cohort and : being informed for the participation to the collection and not having expressed opposition against research program or dead/lost to follow-up without prior opposition expressed against research program, - Inclusion Criteria of Patients from St Louis cohort not enrolled in COBLaNCE study: Blood and tumors from patient having muscle invasive bladder cancer who benefit from neoadjuvant chemotherapy with cisplatine included in COBLaNCE cohort and : being informed for the participation to the collection and not having expressed opposition against research program or dead/lost to follow-up without prior opposition expressed against research program, Exclusion Criteria: * Patients not fulfilling eligibility criteria
Protocol
{'studyType': 'OBSERVATIONAL', 'patientRegistry': False, 'designInfo': {'observationalModel': 'COHORT', 'timePerspective': 'PROSPECTIVE'}, 'enrollmentInfo': {'count': 707, 'type': 'ESTIMATED'}}
Updated at
2024-03-06

1 organization

1 product

2 indications

Organization
University Hospital of Rouen
Product
Neoadjuvant chemotherapy with Cisplatin
Indication
Bladder Cancer
Indication
Genomic Instability